Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA and Giant Cell Arteritis.

Type of Molecule

Small Molecule



Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Atopic Dermatitis n/a
Phase 3
Axial SpA n/a
Phase 2
Crohn's Disease (CD) n/a
Phase 3
Psoriatic Arthritis n/a
Phase 3
Rheumatoid Arthritis (RA) US - Approved, EU - Submitted
Ulcerative Colitis n/a
Phase 3
Giant Cell Arteritis n/a
Phase 3